Autres langues Apollomics, Inc.

Actions

APLM

KYG0411D1079

Temps Différé Nasdaq Autres places de cotation 21:42:06 17/05/2024			Varia. 5j.	Varia. 1 janv.
0,3323 ^USD	-2,26 %		-10,65 %	-65,56 %

08/05	Apollomics, Inc. nomme Robert (Bob) Lin au conseil d'administration	CI
25/04	Avistone Biotechnology Co. Ltd. reçoit l'approbation de l'Administration nationale des produits médicaux de Chine pour le Vebrelinib (APL-101) dans le traitement des gliomes avec gène de fusion Met	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Apollomics Announces Private Placement Financing and Addition to Board of Directors	08/05
Apollomics Announces Private Placement Financing and Addition to Board of Directors	08/05
Apollomics, Inc. Appoints Robert Lin to the Board of Directors	08/05
Apollomics, Inc. announced that it has received $5.75 million in funding	08/05
Apollomics, Inc. announced that it expects to receive $5.75 million in funding	06/05
Apollomics : April 2024 Corporate Presentation	25/04
Avistone Biotechnology Co. Ltd. Receives Approval from the National Medical Products Administration of China for Vebrelinib (APL-101) for the Treatment of Gliomas with Met Fusion Gene	25/04
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene	25/04
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting	10/04
Predicine, Inc. Announces Collaboration with Apollomics, Inc. to Develop Predicinecare as A Companion Diagnostic Assay in Lung Cancer	05/04
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting	02/04
Apollomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results	28/03
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results	28/03
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024	26/03
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024	26/03
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer	04/03
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer	04/03
Apollomics, Inc. Appoints Matthew Plunkett as Chief Financial Officer	04/03
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	07/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Apollomics, Inc.

Actions

APLM

KYG0411D1079

Autres langues

Filtres